The Orthostatic Hypotension Drugs Market is being driven by Increasing prevalence of OH in geriatric population
The Orthostatic Hypotension Drugs Market is expected to grow at a CAGR of 7.7% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 537.4 million. The orthostatic hypotension (OH) drugs market presents a significant business opportunity due to the unmet need for effective and safe pharmacological treatments. Currently, there is a dearth of approved drugs with robust clinical efficiency and a favorable safety profile. To address this gap, several companies are investing in research and development of novel OH drugs. For instance, Theravance Biopharma is developing ampreloxetine (TD?9855), a norepinephrine reuptake inhibitor, to treat symptomatic neurogenic orthostatic hypotension (nOH). Similarly, Cerecor is working on CERC-301, an orally available NR2B-specific NMDA receptor antagonist, for the treatment of nOH associated with neurodegenerative diseases such as Parkinson's disease (PD), multiple system atrophy (MSA), and pure autonomic failure. These pipeline drugs hold promise in catering to the unmet need in OH therapy.
Get more information on Orthostatic Hypotension Drugs Market by requesting a sample report
Which Factors Are Causing a Surge in Market Growth?
The market is segmented based on Product (Midodrine, Northera (droxidopa), Fludrocortisone, Others) Geography (North America, Europe, Asia, Rest of World (ROW)).
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Key Features in Orthostatic Hypotension Drugs Market Research Report
Find out which segment is leading the market by accessing the free PDF report
Orthostatic hypotension, a condition characterized by a significant drop in blood pressure upon standing, is commonly associated with chronic diseases such as neurodegenerative diseases, cardiovascular diseases, diabetes, and endocrine disorders. Combination therapy, including medications like alpha 1-blockers and adrenergic blockers, central actions, fludrocortisone, and midodrine hydrochloride, are used for treatment. Diagnostic tests, including ECG and diagnostic screening, are essential for monitoring and identifying orthostatic hypotension. Chronic disease prevalence, dehydration, nerve damage, and medication changes can also contribute to this condition. Treatment options include fluid intake, compression stockings, and medication adjustments.
The orthostatic hypotension drugs market is a significant segment of the global pharmaceuticals industry, focusing on the development and production of medications for orthostatic hypotension, a condition commonly associated with chronic diseases such as neurodegenerative disorders, cardiovascular diseases, diabetes, and dehydration. This market caters to both generic and non-generic drug manufacturers and providers. The market's growth is driven by the increasing prevalence of chronic conditions due to aging populations. By 2050, approximately one-quarter of the US and European populations are projected to be over 60 years old, necessitating increased demand for orthostatic hypotension treatments. This demographic shift, coupled with ongoing research and development efforts, will fuel market expansion.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
